Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 257

1.

Intravitreal ranibizumab for polypoidal choroidal vasculopathy in non-Asian patients.

Marcus DM, Singh H, Lott MN, Singh J, Marcus MD.

Retina. 2013 Jan;33(1):35-47. doi: 10.1097/IAE.0b013e3182618be0.

PMID:
22990319
2.

One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.

Cheng CK, Peng CH, Chang CK, Hu CC, Chen LJ.

Retina. 2011 May;31(5):846-56. doi: 10.1097/IAE.0b013e3181f84fdf.

PMID:
21317837
3.

Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.

Ricci F, Calabrese A, Regine F, Missiroli F, Ciardella AP.

Retina. 2012 Jul;32(7):1280-8. doi: 10.1097/IAE.0b013e318236e835.

PMID:
22218148
4.

Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.

Lai TY, Lee GK, Luk FO, Lam DS.

Retina. 2011 Sep;31(8):1581-8. doi: 10.1097/IAE.0b013e31820d3f3f.

PMID:
21610566
5.

Factors predictive of outcomes 1 year after 3 monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients.

Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, Ohtsuka H.

Retina. 2013 Oct;33(9):1949-58. doi: 10.1097/IAE.0b013e31828bcafa.

PMID:
23612049
6.

Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation.

Saito M, Iida T, Kano M.

Retina. 2011 Sep;31(8):1589-97. doi: 10.1097/IAE.0b013e31820f4b21.

PMID:
21654347
7.

Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.

Cho HJ, Baek JS, Lee DW, Cho SW, Kim CG, Kim JW.

Retina. 2013 Nov-Dec;33(10):2126-32. doi: 10.1097/IAE.0b013e3182899296.

PMID:
23609123
8.

One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients.

Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, Ohtsuka H, Ariga H.

Am J Ophthalmol. 2012 Jul;154(1):117-124.e1. doi: 10.1016/j.ajo.2011.12.019.

PMID:
22465366
9.

Correlation of indocyanine green angiography and optical coherence tomography findings after intravitreal ranibizumab for polypoidal choroidal vasculopathy.

Ueno C, Gomi F, Sawa M, Nishida K.

Retina. 2012 Nov-Dec;32(10):2006-13. doi: 10.1097/IAE.0b013e31825c1c31.

PMID:
22772392
10.

Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy.

Cho HJ, Baek JS, Lee DW, Kim CG, Kim JW.

Korean J Ophthalmol. 2012 Jun;26(3):157-62. doi: 10.3341/kjo.2012.26.3.157.

11.

Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.

Sagong M, Lim S, Chang W.

Am J Ophthalmol. 2012 May;153(5):873-882.e2. doi: 10.1016/j.ajo.2011.09.031.

PMID:
22265146
12.

Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy.

Cho HJ, Koh KM, Kim HS, Lee TG, Kim CG, Kim JW.

Am J Ophthalmol. 2013 Sep;156(3):524-31.e1. doi: 10.1016/j.ajo.2013.04.029.

PMID:
23769197
13.

Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.

Kang HM, Koh HJ.

Am J Ophthalmol. 2013 Oct;156(4):652-60. doi: 10.1016/j.ajo.2013.05.038.

PMID:
23891333
14.

Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy.

Cho HJ, Kim JW, Lee DW, Cho SW, Kim CG.

Eye (Lond). 2012 Mar;26(3):426-33. doi: 10.1038/eye.2011.324.

15.

Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.

Gomi F, Sawa M, Wakabayashi T, Sasamoto Y, Suzuki M, Tsujikawa M.

Am J Ophthalmol. 2010 Jul;150(1):48-54.e1. doi: 10.1016/j.ajo.2010.02.008.

PMID:
20609707
16.

One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.

Song MH, Ryu HW, Roh YJ.

Ophthalmologica. 2011;226(3):119-26. doi: 10.1159/000329466.

PMID:
21757883
17.

Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.

Moon SW, Kim MS, Kim ES, Yu SY, Kwak HW.

Ophthalmologica. 2011;225(3):169-75. doi: 10.1159/000323811.

PMID:
21273795
18.

Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months.

Hikichi T, Ohtsuka H, Higuchi M, Matsushita T, Ariga H, Kosaka S, Matsushita R, Takami K.

Am J Ophthalmol. 2010 Nov;150(5):674-682.e1. doi: 10.1016/j.ajo.2010.05.026.

PMID:
20691424
19.

Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.

Cho HJ, Kim HS, Jang YS, Han JI, Lew YJ, Lee TG, Kim CG, Kim JW.

Am J Ophthalmol. 2013 Dec;156(6):1192-1200.e1. doi: 10.1016/j.ajo.2013.07.001.

PMID:
24011522
20.

Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.

Saito M, Iida T, Kano M.

Retina. 2012 Jul;32(7):1250-9. doi: 10.1097/IAE.0b013e318236e503.

PMID:
22446886
Items per page

Supplemental Content

Support Center